Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Whole genome–based ultrasensitive circulating tumor DNA clearance as a biomarker of exceptional outcomes with enfortumab vedotin and pembrolizumab in urothelial carcinoma: Preliminary real-world results.

Among evaluable patients, 11 (48%) achieved ctDNA clearance after a median of 3 EVP cycles and 12 (52%) had persistent positivity. The abstract states clearance correlated with exceptional clinical and radiographic outcomes, and persistent positivity identified residual or progressive disease. Median follow-up 13.8 months; 19 of 27 remained under surveillance, including 9 with metastatic disease.

ASCO Genitourinary Cancers Symposium 2026